The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
Open accessAbstract
Very little is known about the comparative long-term effectiveness of novel antipsychotics in relapse prevention, especially in first-episode schizophrenia. Nationwide data from Finnish health care registers were gathered prospectively for all persons with periods of inpatient care due to schizophrenia in Finland during 1972-2014. Altogether 62250 persons were included in the prevalent cohort, and 8719 in the incident (first-episode schizophrenia) cohort. The follow-up for antipsychotic use started at 1996 for the prevalent cohort, and at the first discharge from inpatient care for the incident cases. Within-individual Cox regression models for risk of psychiatric and all-cause hospitalization were constructed to compare risk during antipsychotic use and no use using individual as his/her own control to eliminate selection bias. With follow-up time up to 20 years (median = 14.1, interquartile range = 6.9-20.0), 59% of the prevalent cohort were readmitted to psychiatric inpatient care. Olanzapine long-acting injection (LAI; adjusted hazard ratio = 0.46, 95% confidence interval = 0.36-0.61), clozapine (0.51, 0.49-0.53), and paliperidone LAI (0.51, 0.40-0.66) were associated with the lowest risk of psychiatric rehospitalization in the prevalent cohort. Among first-episode patients, the lowest risks were observed for flupentixol LAI (0.24, 0.12-0.49), olanzapine LAI (0.26, 0.16-0.44), and perphenazine LAI (0.39, 0.31-0.50). Clozapine and LAIs were associated with the lowest risk of all-cause hospitalization in both cohorts. Clozapine and LAIs are the most effective treatments in preventing psychiatric and all-cause hospitalization among chronic and first-episode patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the benefits of reduced treatment gaps with LAI versus oral antipsychotics, studies, particularly those in real-world samples, have demonstrated reduced psychopathology, relapses, hospitalizations, and mortality risk with LAI formulations [98–104].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [102]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, both the clinical benefits and cost-effectiveness of the DPP lifestyle interventions was maintained over a 10-year follow up, even when compared to metformin as a control condition.234,235”
From The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness (2019) · cites this paper as [234]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationTiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Self-citationTiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Self-citationTiihonen, J., Wahlbeck, K., Lönnqvist, J. K., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. K. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 389
Self-citationFrom prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
Tanskanen, A. J., Taipale, H. T., Koponen, M., Tolppanen, A., Hartikainen, S. A., Ahonen, R. S., & Tiihonen, J. (2015) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-015-0140-z · Cited by 200
Self-citationThe Societal Cost of Schizophrenia: A Systematic Review
Jin, H., & Mosweu, I. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0444-6 · Cited by 195
Decline in the Incidence of Schizophrenia in Finnish Cohorts Born From 1954 to 1965
Suvisaari, J., Haukka, J. K., Tanskanen, A. J., & Lönnqvist, J. K. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.733 · Cited by 148
Self-citationHayes, R. D., Downs, J. M., Chang, C., Jackson, R., Shetty, H., Broadbent, M., Hotopf, M. H., & Stewart, R. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu120 · Cited by 130
Selection Bias in Clinical Trials With Antipsychotics
Hofer, A., Hummer, M., Huber, R., Kurz, M., Walch, T., & Fleischhacker, W. W. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00019 · Cited by 112
Research works printed but not linked: 1
- WHO Collaborating Centre for Drug Statistics Methodology, The Anatomical Therapeutic Chemical Classification System. Structure and Principles
Cited by
Sorted by citations
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J. (2020) · World Psychiatry · doi:10.1002/wps.20699 · Cited by 415
Self-citationKishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369
Tiihonen, J., Taipale, H. T., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. J. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4320 · Cited by 313
Self-citationCorrell, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
The clinical course of schizophrenia in women and men—a nation-wide cohort study
Sommer, I. E., Tiihonen, J., van Mourik, A., Tanskanen, A. J., & Taipale, H. T. (2020) · Schizophrenia · doi:10.1038/s41537-020-0102-z · Cited by 179
Self-citationAntipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Lähteenvuo, M., & Tiihonen, J. (2021) · Drugs · doi:10.1007/s40265-021-01556-4 · Cited by 178
Self-citationMortality in schizophrenia: 30-year nationwide follow-up study
Tanskanen, A., Tiihonen, J., & Taipale, H. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12913 · Cited by 134
Self-citationTaipale, H., Schneider-Thoma, J., Pinzón-Espinosa, J., Radua, J., Efthimiou, O., Vinkers, C. H., Mittendorfer-Rutz, E., Cardoner, N., Pintor, L., Tanskanen, A., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3990 · Cited by 129
Self-citationOstuzzi, G., Bertolini, F., Tedeschi, F., Vita, G., Brambilla, P., Fabro, L. D., Gastaldon, C., Papola, D., Purgato, M., Nosari, G., et al. (2022) · World Psychiatry · doi:10.1002/wps.20972 · Cited by 136
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117
Wang, G., Zheng, W., Li, X.-B., Wang, S.-B., Cai, D.-B., Yang, X.-H., Ungvari, G. S., Xiang, Y., & Correll, C. U. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.002 · Cited by 108
Taipale, H., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa111 · Cited by 85
Self-citationOstuzzi, G., Bertolini, F., Giovane, C. D., Tedeschi, F., Bovo, C., Gastaldon, C., Nosè, M., Ogheri, F., Papola, D., Purgato, M., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20071120 · Cited by 86
Solmi, M., Tiihonen, J., Lähteenvuo, M., Tanskanen, A. J., Correll, C. U., & Taipale, H. T. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab087 · Cited by 82
Self-citationMorbidity and mortality in schizophrenia with comorbid substance use disorders
Lähteenvuo, M., Batalla, A., Luykx, J. J., Mittendorfer‐Rutz, E., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13291 · Cited by 78
Self-citationKane, J. M., McEvoy, J. P., Correll, C. U., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 85
Clozapine resistant schizophrenia: Newer avenues of management
Chakrabarti, S. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i8.429 · Cited by 74
Treatment resistant schizophrenia – review and a call to action
Lally, J., & Gaughran, F. (2018) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2018.47 · Cited by 65
Veronese, M., Santangelo, B., Jauhar, S., D’Ambrosio, E., Demjaha, A., Salimbeni, H., Jin, H., McCrone, P., Turkheimer, F., & Howes, O. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00866-7 · Cited by 58
Correll, C. U., Brevig, T., & Brain, C. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2318-x · Cited by 55
Lindenmayer, J., Glick, I. D., Talreja, H., & Underriner, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001225 · Cited by 53
Luykx, J. J., Stam, N., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.267 · Cited by 54
Self-citationLong-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 58
Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review
Lian, L., Kim, D. D., Procyshyn, R. M., Cázares, D., Honer, W. G., & Barr, A. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267808 · Cited by 49
Lian, L., Kim, D. D., Procyshyn, R. M., Fredrikson, D. H., Cázares, D., Honer, W. G., & Barr, A. M. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13202 · Cited by 47
Shah, A., Xie, L., Kariburyo, F., Zhang, Q., & Gore, M. R. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0786-x · Cited by 47
Factors and their weight in reducing life expectancy in schizophrenia
Correll, C. U., Bitter, I., Hoti, F. J., Mehtälä, J., Wooller, A., Pungor, K., & Tiihonen, J. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.10.019 · Cited by 44
Self-citationAbdel‐Baki, A., Thibault, D., Medrano, S., Stip, É., Ladouceur, M., Tahir, M. R., & Potvin, S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12826 · Cited by 44
Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
Lintunen, J., Lähteenvuo, M., Tiihonen, J., Tanskanen, A. J., & Taipale, H. T. (2021) · Schizophrenia · doi:10.1038/s41537-020-00135-y · Cited by 41
Self-citationLin, C., Chen, F.-C., Chan, H., & Hsu, C. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz035 · Cited by 38
Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia
Smith, R. L., Wollmann, B. M., Kyllesø, L., Tran, T. T. A., Tveito, M., & Molden, E. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001507 · Cited by 37
Okoli, C. T. C., Kappi, A. A., Wang, T., Makowski, A., & Cooley, A. T. (2021) · International Journal of Mental Health Nursing · doi:10.1111/inm.12964 · Cited by 36
Daod, E., Krivoy, A., Shoval, G., Zubedat, S., Lally, J., Vadas, L., Weizman, A., Reshef, A., & Bloch, B. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.03.029 · Cited by 36
An international research agenda for clozapine-resistant schizophrenia
Luykx, J. J., González-Díaz, J. M., Guu, T., van der Horst, M. Z., van Dellen, E., Boks, M. P., Gülöksüz, S., DeLisi, L. E., Sommer, I. E., Cummins, R., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00109-8 · Cited by 38
Self-citationComparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder
Hamina, A., Taipale, H. T., Lieslehto, J., Lähteenvuo, M., Tanskanen, A. J., Mittendorfer‐Rutz, E., & Tiihonen, J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.38358 · Cited by 37
Self-citationAntipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
Taipale, H. T., Puranen, A., Mittendorfer‐Rutz, E., Tiihonen, J., Tanskanen, A. J., Červenka, S., & Lähteenvuo, M. (2020) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1854853 · Cited by 31
Self-citationBhavsar, V., Kosidou, K., Widman, L., Orsini, N., Hodsoll, J. P., Dalman, C., & MacCabe, J. H. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz055 · Cited by 31
Miranda, J. J. F., Díaz-Fernández, S., Berardis, D. D., & Lopez-Munoz, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071408 · Cited by 30
Leijala, J., Kampman, O., Suvisaari, J., & Eskelinen, S. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03037-0 · Cited by 35
Takács, P., Czobor, P., Fehér, L., Gimesi-Országh, J., Fadgyas‐Freyler, P., Bacskai, M., Rakonczai, P., Borsi, A., Hegyi, R., Németh, T., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218071 · Cited by 28
Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
Lintunen, J., Taipale, H. T., Tanskanen, A. J., Mittendorfer‐Rutz, E., Tiihonen, J., & Lähteenvuo, M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab004 · Cited by 32
Self-citationKim, S., Kim, S., Koh, M., Choi, G., Kim, J.-J., Paik, I., Kim, S., Choi, Y. S., Lee, Y. H., Suh, J., et al. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13446 · Cited by 27
Weiser, M., Davis, J. M., Brown, C. H., Slade, E. P., Fang, L., Medoff, D. R., Buchanan, R. W., Levi, L. W., Davidson, M., & Kreyenbuhl, J. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111657 · Cited by 24
Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
Cuevas, C. D. L., Sanz, E. J., & de León, J. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s495254 · Cited by 27
Lin, Y., Wu, C., Liu, C., Kuo, P., Chan, H., & Chen, W. J. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac046 · Cited by 22
Schwartz, S. E., Carilli, C., Mian, T., Ruekert, L., & Kumar, A. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.08.232 · Cited by 22
Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review
Álamo, C. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02299-8 · Cited by 23
What is schizophrenia – symptomatology
Striebel, J. M. (2024) · CNS Spectrums · doi:10.1017/s1092852924000622 · Cited by 28
Nielsen, R. E., Hessellund, K. B., Valentin, J. B., & Licht, R. W. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.07.020 · Cited by 21
Tveito, M., Smith, R. L., Molden, E., Haslemo, T., Refsum, H., Hartberg, C. B., Correll, C. U., & Høiseth, G. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000961 · Cited by 21
Mahlich, J., Olbrich, K., Wilk, A., Wimmer, A., & Wolff‐Menzler, C. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00900-y · Cited by 21
Faden, J., Ramirez, C., Martinez, V., & Citrome, L. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2370349 · Cited by 20
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02488-1 · Cited by 19
Tveito, M., Molden, E., Høiseth, G., Correll, C. U., & Smith, R. L. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02768-0 · Cited by 19
General and violent recidivism of former forensic psychiatric patients in Finland
Ojansuu, I., Latvala, A., Kautiainen, H., Forsman, J., Tiihonen, J., & Lähteenvuo, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1157171 · Cited by 17
Self-citationThe Effect of Valproic Acid on Olanzapine Serum Concentration
Tveito, M., Smith, R. L., Høiseth, G., & Molden, E. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001126 · Cited by 17
Taipale, H. T., Lieslehto, J., Lähteenvuo, M., Hamina, A., Tanskanen, A., Mittendorfer‐Rutz, E., Paljärvi, T., Solmi, M., Cipriani, A., Correll, C. U., et al. (2024) · World Psychiatry · doi:10.1002/wps.21205 · Cited by 17
Self-citationLi, P., Benson, C. J., Geng, Z., Seo, S., Patel, C. A., & Doshi, J. A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2189859 · Cited by 16
Antipsychotiques à Action Prolongée: Révision de l’algorithme QAAPAPLE
Stip, É., Abdel‐Baki, A., Roy, M., Bloom, D., & Grignon, S. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719847193 · Cited by 16
Joo, S. W., Shon, S., Choi, G., Koh, M., Cho, S. W., & Lee, J. S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.138 · Cited by 16
Joo, S. W., Kim, H., Jo, Y. T., Ahn, S., Choi, Y. J., Choi, W., Park, S., & Lee, J. S. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.03.010 · Cited by 16
Depot/Long Acting Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
Özgüven, H. D., & Kır, Y. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27480 · Cited by 14
Smith, R. L., Tveito, M., Kyllesø, L., Jukić, M. M., Ingelman‐Sundberg, M., Andreassen, O. A., & Molden, E. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.025 · Cited by 14
Tost, M., González-Rodríguez, A., Aguayo, R., Pedrero, A. Á., Montalvo, I., Barbero, J. D., Gabernet, R., Izquierdo, E., Merodio, I., Monreal, J. A., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110619 · Cited by 14
Pappa, S., Barnett, J., & Mason, K. (2022) · CNS Drugs · doi:10.1007/s40263-022-00976-4 · Cited by 14
Suicidal Behavior and Medication Adherence in Schizophrenic Patients
Warriach, Z. I., Sanchez‐Gonzalez, M. A., & Ferrer, G. F. (2021) · Cureus · doi:10.7759/cureus.12473 · Cited by 17
Strømme, M. F., Mellesdal, L. S., Bartz-Johannesen, C. A., Kroken, R. A., Krogenes, M. L., Mehlum, L., & Johnsen, E. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001497 · Cited by 13
Hodson, N., Majid, M., Vlaev, I., & Singh, S. P. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059526 · Cited by 13
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071101 · Cited by 13
García-Carmona, J. A., Barnett, J., Campos-Navarro, M. P., Mason, K., Valdivia-Muñoz, F., & Pappa, S. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.100111 · Cited by 12
Li, P., Geng, Z., Benson, C. J., Patel, C. A., & Doshi, J. A. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03075-6 · Cited by 13
Strømme, M. F., Mellesdal, L., Bartz-Johannessen, C., Kroken, R. A., Krogenes, M. L., Mehlum, L. I., & Johnsen, E. (2022) · NORA - Norwegian Open Research Archives · Cited by 12
Catalán, A., García, L., Sánchez-Alonso, S., Gil, P., Díaz‐Marsá, M., Olivares, J. M., Baltanás, T. R., Pérez‐Martín, J., Torres, M. Á. G., Ovejero, S., et al. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13098 · Cited by 12
Oral Versus Long-Acting Injectable Antipsychotic Treatment for People With Severe Schizophrenia
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2021) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001299 · Cited by 12
Li, Q., Li, X. R., Ye, C., Jia, M., & Si, T. (2023) · CNS Drugs · doi:10.1007/s40263-023-01028-1 · Cited by 12
Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia
Hamina, A., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2020) · Medical Care · doi:10.1097/mlr.0000000000001369 · Cited by 11
Self-citationDoes antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?
Faden, J., Kiryankova-Dalseth, N., Barghini, R., & Citrome, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1847274 · Cited by 11
Liu, J., Wang, Q., Su, L., Yang, L., Zou, L., & Bai, L. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03728-2 · Cited by 11
Giron‐Hernandez, C., Han, J. H., Alberio, R., Singh, A., García‐Portilla, M. P., Pompili, M., Knight, R. K., Richarz, U., Gopal, S., & Antunes, J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s400342 · Cited by 10
Patel, R. S., & Tankersley, W. E. (2021) · CNS Spectrums · doi:10.1017/s109285292100050x · Cited by 10
Doshi, J. A., Li, P., Geng, Z., Seo, S., Patel, C. A., & Benson, C. J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20230142 · Cited by 9
Preventing disease progression in schizophrenia: What are we waiting for
Lieberman, J. A., Mendelsohn, A. I., Goldberg, T. E., & Emsley, R. A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.12.042 · Cited by 9
Joo, S. W., Kim, H., Jo, Y. T., Choi, Y. J., Ahn, S., & Lee, J. S. (2021) · Psychological Medicine · doi:10.1017/s0033291721001379 · Cited by 9
Brodeur, S., Vanasse, A., Courteau, J., Stip, É., LESAGE, A. D., Fleury, M., Courteau, M., & Roy, M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13413 · Cited by 11
Baune, B. T. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2287612 · Cited by 10
Suetani, S., Siskind, D. J., Phillipou, A., Waterreus, A. J., Morgan, V. A., & Castle, D. J. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211009602 · Cited by 9
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2022) · Biomedicines · doi:10.3390/biomedicines11010042 · Cited by 9
Tveito, M., Høiseth, G., Haslemo, T., Molden, E., & Smith, R. L. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03114-z · Cited by 9
Aguglia, A., Fusar‐Poli, L., Amerio, A., Placenti, V., Concerto, C., Martinotti, G., Carrà, G., Bartoli, F., D’Agostino, A., Serafini, G., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.784366 · Cited by 8
Üçok, A., Yağcıoğlu, E. A., Aydin, M., Kara, İ., Erbasan, V., Türkoğlu, Ö., Ergün, S., Chousein, M., Oktar, N., Ucar, N., et al. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000348 · Cited by 8
Díaz-Fernández, S., López-Muñoz, F., & Fernández-Miranda, J. J. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000581 · Cited by 8
Erickson, B., Ehrie, J., Murray, S., Dougherty, R. J., Wainberg, M. L., Dixon, L. B., & Goldman, M. L. (2022) · Psychiatric Services · doi:10.1176/appi.ps.20220196 · Cited by 8
Schmidt-Kraepelin, C., Feyerabend, S., Engelke, C., Riesbeck, M., Meisenzahl‐Lechner, E., Gäebel, W., Verde, P.-E., Kolbe, H., Correll, C. U., Leucht, S., et al. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01063-4 · Cited by 8
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan
Ballon, J. S., Kahn, R. S., Arevalo, C., Dunbar, M., McDonnell, D., & Correll, C. U. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15511 · Cited by 7
Chan, H., Huang, C.-Y., & Yen, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03513-7 · Cited by 7
Cristarella, T., Castillon, G., Nepveu, J.-F., & Moride, Y. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.915 · Cited by 7
Hattori, S., Suda, A., Kishida, I., Miyauchi, M., Shiraishi, Y., Noguchi, N., Furuno, T., Asami, T., Fujibayashi, M., Tsujita, N., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04617-y · Cited by 7
Metadata
- Authors
- Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J.
- Affiliations
- University of Eastern Finland (FI)
- EPID Research Oy, Espoo, Finland
- Corresponding author
- Tiihonen, Jari
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-20
- Volume
- 44
- Issue
- 6
- Pages
- 1381-1387
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6192491
- OpenAlex
- W2776169777
- Cited by
- 153
- References
- 15
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 16 · 2023: 16 · 2022: 25 · 2021: 35 · 2020: 21 · 2019: 21 · 2018: 7
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UEF eRepo (University of Eastern Finland) (submittedVersion, cc-by-nc)
- Funders
- Finnish Ministry of Social Affairs
- Niuvanniemi Hospital
- Eli Lilly (F1D-HL-0341)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs
- MeSH terms
- Paliperidone Palmitate, Olanzapine, Adult, Aged, Clozapine, Female, Finland, Flupenthixol, Follow-Up Studies, Humans, Male, Middle Aged, Patient Readmission, Perphenazine, Schizophrenia, Antipsychotic Agents, Incidence, Prevalence, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
